Jason Schmit
Optometrist · Sioux Falls, SDNPI 1124220322
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,130 of the $78,746 with a category attached, or 71.3%. 24 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 56.6% of the total. Reporting peaked in 2019 at $31,882 and has fallen 98.5% since, to $463 in 2025. Among optometrist clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $353.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$45K
- Shire North American Group Inc$20K
- Novartis$5K
- Johnson & Johnson Surgical Vision, Inc.$4K
- Amgen$2K
- Carl Zeiss Meditec, Inc.$1K
- plus $2K from 18 others
Across 6 payments — averaging $71,187 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$427K
What the payments were for
- Consulting fees$7,48510%
- Speaking & faculty fees$56,13071%
- Travel & lodging$10,37113%
- Food & beverage$4,6446%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 60 | $44,574 |
| Shire North American Group Inc | 43 | $19,698 |
| Novartis | 25 | $5,227 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $3,839 |
| Amgen(2 entities) | 18 | $1,634 |
| Carl Zeiss Meditec, Inc. | 6 | $1,465 |
| Tearlab Corp | 2 | $520 |
| Glaukos Corporation | 6 | $248 |
| Mallinckrodt Hospital Products Inc. | 7 | $235 |
| AbbVie | 9 | $229 |
| Oyster Point Pharma, Inc. | 7 | $200 |
| Alcon | 7 | $129 |
| Sight Sciences, Inc. | 4 | $128 |
| Dompe US, Inc. | 6 | $107 |
| Biotissue Holdings Inc. | 4 | $98 |
| Kala Pharmaceuticals, Inc. | 3 | $77 |
| Ocular Therapeutix, Inc. | 2 | $68 |
| Harrow Eye, LLC | 2 | $64 |
| Rxsight Inc | 2 | $54 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $47 |
| Tarsus Pharmaceuticals, Inc. | 1 | $41 |
| Rayner Intraocular Lenses Limited | 1 | $32 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$43,655
- XIIDRA$22,531
- MEL 90$1,358
- TEPEZZA$1,324
- TearLab Osmolarity System$500
How this compares
$78,746 in reported general payments places this provider in the 95th percentile of 206 optometrist providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 108 | $80,571 |
| XiidraLifitegrast | 28 | $29,296 |
| XdemvyLotilaner | 12 | $23,097 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,910 |
| Cyclosporine | 15 | $8,894 |
| Prednisolone Acetate | 73 | $2,817 |
| Fluorometholone | 25 | $1,754 |
| Ketorolac Tromethamine | 22 | $554 |
| Pilocarpine Hcl | 15 | $482 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 28 | $395 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $350 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $278 |
| Ofloxacin | 22 | $272 |
| Latanoprost | 47 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $229 | $80,571108 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $18 | $42,20645 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $41 | $23,09712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 optometrist providers in South Dakota.
Other optometrist in Sioux Falls
- Justin SchweitzerSioux Falls$753K
- Mitchel IbachSioux Falls$395K
- Jeffery SaylerSioux Falls$8K
- Kayla KarpukSioux Falls$6K
- Travis LehrSioux Falls$5K
- Matthew ClarkeSioux Falls$5K
- Ryan HaiarSioux Falls$4K
- Kristen KramlichSioux Falls$4K
- Joshua TimsSioux Falls$4K
- Larae ZimprichSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.